KIDRON NADAV 4

What Happened

• Nadav Kidron, President, CEO and Director of Oramed Pharmaceuticals (ORMP), had 109,000 performance stock units (PSUs) vest on January 22, 2026. The PSUs converted into 109,000 shares of common stock that were issued to him for no consideration (reported as derivative conversion under transaction code M). The Form 4 lists the shares acquired at $0.00; there is no cash purchase or open-market sale reported.

Key Details

• Transaction date: January 22, 2026
• Transaction type/code: Exercise/conversion of derivative (M) — PSUs converted to common stock
• Shares involved: 109,000 shares received; reported acquisition price $0.00
• Footnotes: F1 — vesting of PSUs granted Dec 31, 2025 upon achieving a specified share-price target; shares received for no consideration. F2 — each PSU converted to one share upon meeting performance criteria.
• Shares owned after transaction: Not specified in the provided filing excerpt (see full Form 4 for total beneficial ownership)
• Filing timing: Form filed Jan 29, 2026 (7 days after the transaction date); Form 4s are generally required within 2 business days, so this filing appears late based on the provided dates.

Context

• This was not a market purchase or sale but the conversion/issuance of shares tied to performance awards — common executive compensation practice. Such award vesting reflects achievement of pre-set performance criteria and does not by itself indicate buying or selling intent. For full holdings and any subsequent sales, consult the complete Form 4 filing and future updates.